27-May-2019: The global artemisinin
combination therapy (ACT) market size is expected to reach USD 697.9 million by
2025, according to a new report by Grand View Research, Inc., progressing at a
CAGR of 8.5% during the forecast period. Rising adoption rate of ACTs coupled
with growing government initiatives to combat malaria epidemic is anticipated
to stoke the growth of the market. Furthermore, expanding pipeline and new
product approvals are driving the market.
Currently, 6 ACTs are
recommended by WHO for the treatment of uncomplicated malaria, which are
Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine
(AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ),
Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate
(PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced
likelihood of developing resistance. Over the years, access to artemisinin
combination therapy has expanded considerably. In 2016, ACTs were used as
first-line treatment in almost 80 countries.
Increasing R & D
initiatives by pharma-emerging countries such as India and China are revving up
the adoption rate of ACTs. Rising demand from malaria endemic countries such as
Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for
new antimalarial drugs is widening and some of them have been introduced
recently. These are some of the factors that are propelling the ACT market.
WHO states the necessity for
treating uncomplicated malaria, the most serious form of the disease, with ACTs
as they are the best treatment available. ACTs are recommended over other
treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin
monotherapies, because parasites have developed resistance to these medicines.
Malaria is one of the most
distressing diseases across the globe with more than 200 million new cases
reported each year. According to Medicines Malaria Venture (MMV), a total of
445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is
continuing to increase globally and climate change is projected to fuel the
trend.
In
depth research report on Artemisinin Combination Therapy Market
Further
key findings from the report suggest:
· AL was
the largest segment in 2017 due to the fact that it was the first ACT to be
marketed and prequalified by WHO for its efficacy, safety, and quality. It is
available in more than 60 countries and is the only ACT approved by U.S. FDA
· MEA
held the largest share in the market for ACTs due to growing initiatives by
government and non-government organizations to raise awareness
· Asia
Pacific also held a prominent position in the market owing to factors such as
large production base of artemisinin herbs coupled with rising access to ACT in
this region
· Major
players operating in the market are Novartis, Sanofi, Cipla, Ajanta Pharma,
Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals
· Key
players are adopting different strategies to increase their market share such
as increasing geographic presence, R & D, new product development, and
indication extension.
Grand View Research has
segmented the global artemisinin combination therapy market on the basis of
type and region:
Artemisinin
Combination Therapy Type Outlook (Revenue, USD Million, 2014 - 2025)
· Artemether-Lumefantrine
· Artesunate-Amodiaquine
· Dihydroartemisinin-Piperaquine
· Artesunate-Mefloquine
· Artesunate-Sulfadoxine-Pyrimethamine
· Pyronaridine-Artesunate
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment